Ezogabine: all 23 studies that test it

Page 1 of 1. Open to participants first (0), then studies with results posted, then the rest; newest registration first within each.

• An Open-Label Extension of the Study XEN496 (Ezogabine) in Children With KCNQ2-DEETerminatedNCT04912856Phase 3Results posted
• XEN496 (Ezogabine) in Children With KCNQ2 Developmental and Epileptic EncephalopathyTerminatedNCT04639310Phase 3Results posted
• Study to Treat Major Depressive Disorder With a New MedicationCompletedNCT03043560Phase 2Results posted
• Clinical Trial of Ezogabine (Retigabine) in ALS SubjectsCompletedNCT02450552Phase 2Results posted
• Study to Treat Major Depressive Disorder (MDD) With a New MedicationCompletedNCT02149836Phase 2Results posted
• A Long-term, Safety, Tolerability, and Efficacy Study of Retigabine Immediate-release (IR) in Asian Adults With Partial Onset SeizuresCompletedNCT01777139Phase 3Results posted
• Dose-Optimization, Adjunctive Treatment Study of Ezogabine/Retigabine Immediate Release in Partial-onset SeizuresTerminatedNCT01721317Phase 4Results posted
• Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGSTerminatedNCT01668654Phase 3Results posted
• Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset SeizuresTerminatedNCT01648101Phase 3Results posted
• An Open Label Study to Evaluate the Effects of Ezogabine/Retigabine Added to Existing Anti-epileptic Drug(s) on Urinary Voiding Function in Subjects With Partial Onset SeizuresTerminatedNCT01607346Phase 4Results posted
• Study in Pediatric Subjects With EpilepsyTerminatedNCT01494584Phase 2Results posted
• Long-Term Safety Study of Retigabine Immediate Release (IR) as Adjunctive Therapy in the Treatment of Adults With Partial-Onset Seizures (POS)CompletedNCT01336621Phase 3Results posted
• Study of Retigabine Immediate Release as Adjunctive Therapy to Specified Monotherapy Antiepileptic Treatments in Adults With Partial-Onset SeizuresCompletedNCT01227902Phase 3Results posted
• Safety/Efficacy Study of Retigabine vs. Placebo in Post-Herpetic Neuralgia (PHN)CompletedNCT00612105Phase 2Results posted
• Open-Label Extension Study of the Phase 3 VRX-RET-E22-302 Double-Blind Trial. 115097TerminatedNCT00310388Phase 3Results posted
• Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind TrialCompletedNCT00310375Phase 3Results posted
• Retigabine Efficacy and Safety Trial for Partial Onset Refractory Seizures in EpilepsyCompletedNCT00235755Phase 3Results posted
• Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in EpilepsyCompletedNCT00232596Phase 3Results posted
• Cortical Excitability Changes Induced by Retigabine: a Transcranial Magnetic Stimulation StudyCompletedNCT01823159Phase 3
• Pharmacokinetic Study of Retigabine Extended Release (XR) Formulation in Healthy Adult Japanese and Caucasian SubjectsWithdrawnNCT01691872Phase 1
• An Open-label, Single-centre Study Evaluating the Pharmacokinetics of Digoxin Alone and When Administered at Various Doses of Ezogabine/Retigabine in Healthy Adults. The Pharmacokinetics of Ezogabine/Retigabine and the N-acetyl Metabolite of Ezogabine/Retigabine (NAMR) Will Also be AssessedCompletedNCT01583036Phase 1
• Effect of Haemodialysis on the Pharmacokinetics of Ezogabine/Retigabine and Its N-acetyl MetaboliteCompletedNCT01480609Phase 1
• Crossover Study to Evaluate the Pharmacokinetics of Ezogabine/Retigabine in Taiwanese SubjectsCompletedNCT01462669Phase 1

← Ezogabine overview